SECURITIES AND EXCHANGE COMMISSION Washington, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 1997 Repligen Corporation (Exact name of registrant as specified in its charter) Delaware 0-14656 04-2729386 (State or other jurisdiction (Commission file number) (I.R.S. Employer of incorporation) Identification No.) 117 Fourth Avenue Needham, Massachusetts 02194 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (781)449-9560 ITEM 5. OTHER EVENTS On December 31, 1997, the Registrant publicly disseminated a press release announcing a $2.0 million investment in the Company by Biotechnology Value Fund, L.P. and affiliates ("BVF") of San Francisco and Four Partners, L.P. of New York. The investment involves the sale of common stock and warrants. The press release announcing the investment is incorporated herein by reference and filed as Exhibit 99 hereto. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS (c) Exhibits. Exhibit 99 The Registrant's Press Release dated December 31, 1997. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Repligen Corporation (Registrant) Date: January 2, 1998 By: /S/ Walter C. Herlihy -------------------------- Chief Executive Officer Signing on behalf of the Registrant and as Principal Financial and Accounting Officer EXHIBIT INDEX Exhibit Number Description Sequential Page Number 99 The Registrant's Press Release 5 dated December 31, 1997